文献速递新发突发、热带与寄生虫病

安第斯病毒相关心肺综合征:诊断方法、临床管理与证据缺口范围综述

Andes virus-associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps-a scoping review.
PubMed 文献 · Clin Microbiol Infect · 2026-06-20

血清学为常规主要诊断手段,RT-PCR用于疑难病例,未发现经验证的床旁检测。治疗以支持为主,专科中心ECMO管理似与生存改善相关,但证据为观察性;无获批抗病毒药物。

要点

  • 血清学是常规诊断主要手段,RT-PCR用于疑难病例
  • 未发现经验证的安第斯病毒特异性床旁检测
  • 重症支持治疗包括机械通气、血管升压药和ECMO

核心结论

  • 安第斯病毒相关心肺综合征仍是高死亡率疾病,诊断和治疗领域证据有限。
  • 病死率随时间下降反映临床经验积累而非药物进展。

研究设计与样本

  • 范围综述检索PubMed/MEDLINE、Embase、Scopus、Cochrane Library和ClinicalTrials.gov,时间1993年1月1日至2026年5月13日。

主要发现

  • 血清学在常规实践中作为主要诊断方式,RT-PCR保留用于诊断困难病例。
  • 管理完全为支持性,重症病例使用机械通气、血管升压药和ECMO。
  • 在专科中心,基于ECMO的管理与生存改善相关,但证据仍为观察性。
  • 无获批抗病毒治疗;皮质类固醇和免疫血浆证据有限且不确定。
  • 长期结局特征不清,近期数据提示出院后显著发病率。

关键数值与推荐

  • 病例确认标准为纳入研究报告的标准,主要为安第斯病毒特异性血清学和/或分子检测。
  • 未进行正式偏倚风险评估,研究按预定纳入排除标准评估资格。

临床怎么用

  • 临床怀疑安第斯病毒相关心肺综合征时,常规诊断可依血清学,疑难病例加做RT-PCR。
  • 重症管理以支持治疗为主,包括机械通气、血管升压药,专科中心可考虑ECMO。
  • 目前无获批抗病毒药物,不推荐常规使用皮质类固醇或免疫血浆。

局限性

  • 未进行正式偏倚风险评估,证据以回顾性队列和病例报告为主。
  • 未评估诊断试验准确性 against 共同参考标准。
  • 治疗证据主要为观察性,长期结局数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Andes virus-associated hantavirus cardiopulmonary syndrome (ANDV-HCPS) is a severe zoonotic disease endemic to South America, characterized by high mortality and a unique capacity for person-to-person transmission. The 2026 MV Hondius cruise ship outbreak underscored its potential for international dissemination. OBJECTIVES: To map the available evidence on diagnostic approaches and clinical management of ANDV-HCPS, and to identify key knowledge gaps and research priorities. METHODS: Data sources: PubMed/MEDLINE, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov, searched from 1 January 1993 to 13 May 2026. STUDY ELIGIBILITY CRITERIA: Original studies reporting clinical data on confirmed or probable ANDV-HCPS, including clinical trials, observational studies, surveillance cohorts, case series, and case reports. PARTICIPANTS: Patients with confirmed or probable ANDV-HCPS. TESTS: Diagnostic approaches, clinical management strategies, and therapeutic interventions evaluated across included studies. REFERENCE STANDARD: Not applicable; this scoping review did not assess diagnostic test accuracy against a common reference standard. Case confirmation criteria were those reported in the included studies, mainly ANDV-specific serology and/or molecular testing. ASSESSMENT OF RISK OF BIAS: No formal risk-of-bias assessment was performed. Studies were assessed for eligibility against predefined inclusion and exclusion criteria and charted using a predefined extraction framework, consistent with the scoping-review objective of mapping available evidence rather than weighting studies by methodological quality. METHODS OF DATA SYNTHESIS: Data were charted using a predefined extraction framework and synthesized narratively by clinical domain. RESULTS: Forty studies were included, predominantly retrospective cohorts and case reports from Chile and Argentina. Across the included studies, serology served as the primary diagnostic modality in routine practice, with RT-PCR reserved for diagnostically challenging cases; however, no validated ANDV-specific point-of-care test was identified. Management was entirely supportive, with mechanical ventilation, vasopressors, and extracorporeal membrane oxygenation (ECMO) used in severe cases; ECMO-based management was associated with improved survival in specialist centres, although evidence remains observational. No approved antiviral therapy exists; evidence for corticosteroids and immune plasma remains limited and inconclusive. Long-term outcomes are poorly characterized, with recent data suggesting substantial post-discharge morbidity. DISCUSSION: ANDV-HCPS remains a high-mortality disease with limited evidence across diagnostic and therapeutic domains. The decline over time in case fatality rates reflects accumulated clinical expertise rather than pharmacological advances. Key priorities include strengthening early diagnostic pathways, standardizing clinical escalation criteria, and generating prospective multicentre evidence on therapeutic interventions, building on prior experience and research efforts in endemic settings.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Fama F, Molà F, Rizzo A, et al. Andes virus-associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps-a scoping review. Clin Microbiol Infect. 2026. PMID: 42323110. doi:10.1016/j.cmi.2026.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。